 |
| A medic in protective suit examining the patient some where in Paris |
Image Source: Nasal Treatment by a Medic somewhere in Paris
Senses of Smell and Tastes might be attacked by covid-19
Few reports
are in circulation for weeks that human senses of smell and tastes might be
fragile caused by novel coronavirus attack.
This report
gets more credibility when British Association of Otorhinolaryngology endorses
that also consider anosmia useful symptom while screening the virus, supporting
the claims from the reports from South Korea, China, and Italy, and recorded
higher numbers in UK clinics as of normal routine.
The World
Health organization officials stated on Monday that they were tracking the
matter to find out any possible clue.
“We are
reaching out to a number of countries and looking at the cases that have
already been reported to see if this is a common feature,” stated by Maria Van
Kerkhove, the head of the WHO’s emerging diseases and zoonoses, “We didn’t have
answer to his yet.”
Coronaviurs vaccine –progress and development pace
 |
| Coronavirus Vaccine has been studying somewhere in Singapore |
At present, the most effective measure-containment
strategies just succeeded only to slow down the spread of respiratory disease
covid-19. Declaring it as a pandemic by the World Health Organization turns the
attention towards the development of a vaccine because the only vaccine can
prevent covid-19 infection.
Almost 35 companies and academic institutions are competing
to produce the coronavirus vaccine worldwide. A biotech firm Moderna-Boston
Based-is the first one that came up with a trial test on humans.
Must say thanks to China that sharing the sequence of
genetic virus SARS-CoV-2 caused Covid-9 early in January with the whole world
to open the door of study and research on this lives grow virus and finding the
reasons how it invades the human body and makes human sick.
In the recent past, two other epidemics caused by
coronaviruses –severe acute respiratory syndrome (Sars) in 2002-4 in china, and
Middle East respiratory syndrome (Mers), which were outbreaks in 2012 in Saudi
Arabia. Consequently, the work started on a vaccine but soon become part of
shelved when SARS and MERS were contained. The Novavax, Maryland-based, company
now re-started work on those vaccines for pandemic covid-19, claimed that
several candidates are ready to take in vaccines on a trial basis.
All vaccines are produced on the same basic principle. Thus
purpose is to hit the part or all of the pathogen present inside the human
immune system, often using injection having a low dose, making the system
healthy by producing antibodies against the pathogen.
Coronavirus
Vaccine-Italy Based Researches claim rare mutation
Recently two pieces of research conducted by two Italian
scientist teams independently suggest that the SARS-CoV-2 coronavirus that
becomes the cause of the global health crisis mutates slowly relatively. This means that any produced vaccine used to
protect the people from getting infected should have the same effective
performance worldwide over a long period of time.
The two scientist teams' one from Lazzaro SpallanzaniNational Institute for Infectious Diseases (IRCCS) in Rome and the second one
from the Forensic Division of the Department of Biomedical Science and Health
(DSBSP) performed a genetic sequence tests on samples of virus taken from
different patients. The results show five new variants of SARS-Cov-2 discovered
when comparing with sequenced analyses of the samples of the sent out by China
originated from Wuhan outbreaks some two months ago.
The very slow mutation of Covid-19, indeed, seems to be good
news for the world vaccine producers.
This point of view is further endorsed by the work done at
John Hopkins University and including other infectious disease specialists from
around the globe.
Coronavirus Vaccine: Russian Announced Trial Testing on Animals
The testing of the prototype vaccine has been started by
Russian Scientists against coronavirus on animals in the laboratory in Siberia,
Reported by Russia's consumer health regulatory on March 20, Friday.
The six different technologies have been used to make this
prototype vaccine.
They examined the vaccine from the perspective of
effectiveness, and how much doses would be needed to control it. The regulator
said.
Fuji Participation
The treatment of infected patients of coronavirus based on a
clinical trial in Wuhan and Shenzhen using the Japan-based medicine for flue
–favipiravir found effective in reducing the time period from 11 days to 4
days, said Chinese Medical Authorities.
The outcomes of favipiravir, also known as avigan, developed
by the subsidiary of the Fujifilm (Japan-based company) show health signals in
clinical trials involving 340 patients in total from both the cities Shenzhen
and Wuhan.
"It has a high degree of safety and is clearly
effective in treatment," Zhang Xinmin, an official at China's science and
technology ministry, spoke to reports on Tuesday.
However, the company Fujifilm Toyama Chemical- had denied
commenting on this claim.
The avigan, developed in 2014, has shown poor performance
with patients having severe symptoms.
"We've given Avigan 70 to 80 patients, but it doesn't seem to work
well when the virus has already multiplied," as shared by the Japanese
Health Ministry source with the Mainchi Shimbun newspaper, as per Guardian
report.
In Japan, the doses of the same drugs have been given to the
patients affected with novel coronavirus by the doctors having the degree of
symptoms from mild to moderate. In addition, the data from these trials have
not been shared in any science journal.
The drug was supplied to Guinea in 2016 by Japan, preventing
people from the Ebola virus outbreaks.
The drug may get approval as soon as possible in May, an
official at health ministry told Mainchi. Still, it is subjected to the results
of clinical research-meaning that if the results are delayed, approval could be
delayed.
Coronavirus Vaccine-First Clinical trial testing on human
The first clinical trial has been conducted by the drug
maker company, Moderna, on Monday by injecting its produced vaccine into a 43
years old Lady, Jennifer Haller.
This experimental test has started at Kaiser Permanente
Washington Health Research Institute in Seattle. This trial-based clinical test
will be applying on 45 healthy adult candidates age between 18 to 55 years in
the first phase in the next six weeks.
The scientific name of this vaccine is mRNA-1273. This
development is the result of joint efforts of NIAID, National Institute of
Allergy and Infectious Diseases and their collaborators at biotech company
Moderna, Inc located in Cambridge, Massachusetts. Also, CEPI, Coalition for
Epidemic Preparedness Innovation, has also cooperated in the preparation of
this vaccine.
Latest coronavirus vaccines updated will be shared as announced.
Visit afaqnewsfourm to get coronavirus vaccines latest news